Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 21, 2022HaematologicaOpen Access

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAnthony R. MatoMemorial Sloan Kettering Cancer CenterBTBoxiong TangUniversidad San CarlosSASoraya AzmiBeiGene (China)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mato et al. (2022) studied this question.

synapsesocial.com/papers/6ab5d89dd64e34c15d4c45dchttps://doi.org/10.3324/haematol.2021.280376
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion2020 · 104 citations
  2. 2Observational Studies: Cohort and Case-Control Studies2010 · 965 citations
  3. 3Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis2018 · 460 citations
  4. 4Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry2019 · 33 citations
  5. 5Chemotherapy-free frontline therapy for CLL: is it worth it?2020 · 18 citations